Document 6ROa8EoRzQzdgMXkLNb8QjEaE

TURNER Eric (CIT) De: Envoy: : Objet: Zazenski, Rich (LNA) [Rich.Zazenski@america.luzenac.com] 18 October 2000 14:14 Bernstein, Robert (LNA); Me, Rich (LNA); Turner, Eric (LNA) CTFA Conference Call Minutes > Talc Interested Party Conference Call Minutes > October 16, 2000 > > Present for the Call: > Mike Chudkowski - Johnson & Johnson > Bill Ashton - Johnson & Johnson > John Hopkins - Johnson & Johnson (consultant) > Bill Dressier - Clairol > Rich Zazenski - Luzenac > Gabriela Adam-Rodwell - Mary Kay > Charlie Sewall - Procter & Gamble > John Kelse - RT Vanderbilt > Linda Loretz - CTFA > Jerry McEwen - CTFA V th is conference call was scheduled to discuss how to address the NTP draft > background document conclusion that non-asbestiform talc is "reasonably > anticipated to be a human carcinogen" for purposes of listing in the 10th > Report on Carcinogens. > > CTFA has received bids for two projects to address the Talc issue. The > first is for a crisis management plan (Nichols-Dezenhall), and the second > is for The Weinberg Group to manage epidemiology reviews, including > arranging for a speaker(s) at the Board of Scientific Counselors meeting > in December. The total cost for both projects will be ~$150,000. The > process can start once enough financial support has been committed. > > While the ovarian epidemiology is the issue of greatest concern in the > draft document, the NTP inhalation study is not entirely dismissed. > Possible reviewers to address the inhalation issue might be Dr. > Oberdorster, Dr. Jay Goodman or Dr. Al W ehner. It was noted that NTP > itself had concluded that the study results reflected lung overload, and > had raised the question of human relevance. A recent (2000) publication > in Inhalation Toxicology reported the results of an ILSI Workshop which -eached the same conclusion. W > JKelse reported that RT Vanderbilt would be preparing a defense of Talc > (containing asbestiform fibers) which would include reviews of both > epidemiology and animal studies. It was agreed that CTFA and RT > Vanderbilt should keep each other informed to make sure there are no > inconsistencies and that the same reviewers are not being used. > > It was noted that, if non-asbestiform talc is listed in the RoC, the > consequences could depend significantly on how it is listed (i.e., loose > powder only, and restricted to use in the perineal area, would be much > preferable to a listing without qualifiers). > > Talc Task Force members are asked to work with their management to get > funding commitments ASAP. J. Kelse will contact the National Paint > Coatings Association to see if they will commit funds to this effort. The > Talc activities will also be noted in a Safety and Regulatory Toxicology > meeting taking place tomorrow, to see if there are additional companies > interested. > > The next steps, following commitment of the necessary funds, are: > - Nichols-Dezenhall will be asked to provide a proposal specifying the ^ l Protected Document - Subject to Protective Order 1 Of 1 ^ r\ r^osXVc ? IMERYS 240345 Pltf_IM ERYS_00tM ERYS240345 > elements of their crisis management response. The work will be > coordinated with the Public Affairs people in the companies, and with > Irene Malbin, V .P . of Public Affairs at CTFA. > - The Weinberg Group will be asked to begin to organize for the project. > The Task Force will be asked to recommend reviewers and provide a basis > for the recommendations. The Weinberg Group will be asked for names of > their epidemiology people. ,J > - The availability of additional relevant data not included in the NTP > draft document will be determined. > - MChudkowski and LLoretz will coordinate on consultants) to address the > lung issue. . > - LLoretz will send out invoices to Task Force companies. > Because written comments are due by December 1, and will require review by > Task Force participants, the project needs to be on a very fast track. By > the end of this week, the timing should be established. Protected Document - Subject to Protective Order 1 Of 1 IMERYS 240346 Pltf_IM ERYS_00tM fiRYS240346